STOCK TITAN

United Therapeutics (NASDAQ: UTHR) grants stock units and options to director Kurzweil

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics Corp director Ray Kurzweil received annual equity awards consisting of 380 restricted stock units and 1,190 stock options on July 22, 2026. The awards vest in full on the earlier of the one-year anniversary of the grant or the next Annual Meeting, anticipated on June 25, 2027. The options carry an exercise price of $527.07 per share and expire on July 22, 2033. Following these awards, he directly holds 13,320 shares of United Therapeutics common stock. The restricted stock units have no expiration date and each converts into one share upon vesting.

Positive

  • None.

Negative

  • None.
Insider KURZWEIL RAY
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Unit F1, F2, F3, F4 380 $0.00 $0.00
Grant/Award Stock Option F2, F3 1,190 $0.00 $0.00
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Unit — 380 shares (Direct); Stock Option — 1,190 shares (Direct); Common Stock — 13,320 shares (Direct)
Footnotes (4)
  1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
  2. F2. Annual non-employee director award.
  3. F3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
  4. F4. Not applicable as restricted stock units do not have an expiration date.
Restricted stock units granted 380 units Annual non-employee director award granted on 2026-07-22
Stock options granted 1,190 options Annual non-employee director award granted on 2026-07-22
Option exercise price $527.07 per share Exercise price for the 1,190 stock options granted
Option expiration date July 22, 2033 Expiration of stock options granted to Ray Kurzweil
Anticipated vesting/meeting date June 25, 2027 Anticipated date of next Annual Meeting; awards vest by this date or one-year anniversary
Common shares held after awards 13,320 shares Directly held United Therapeutics common stock following reported awards
Restricted Stock Unit financial
"Each restricted stock unit represents the right to receive, following vesting, one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option financial
"Stock Option award covering 1,190.0000 underlying shares of common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Annual non-employee director award financial
"Annual non-employee director award described in the footnotes to the equity grants"
exercise price financial
"Stock option grant with an exercise price of 527.0700 per share of common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did United Therapeutics (UTHR) grant to Ray Kurzweil?

Ray Kurzweil received 380 restricted stock units and 1,190 stock options as annual non-employee director awards. Each restricted stock unit converts into one common share upon vesting, while the options are exercisable for common stock at a fixed price.

What is the exercise price of Ray Kurzweil’s new United Therapeutics (UTHR) stock options?

The granted stock options have an exercise price of $527.07 per share. This is the price at which Kurzweil may purchase United Therapeutics common stock under the option grant once the options are vested and through their stated expiration date.

When do Ray Kurzweil’s new United Therapeutics (UTHR) director awards vest?

The annual director awards become fully vested on the earlier of the one-year anniversary of the July 22, 2026 grant date or the next Annual Meeting. June 25, 2027 is identified as the anticipated date of that next Annual Meeting of Shareholders.

When do Ray Kurzweil’s United Therapeutics (UTHR) stock options expire?

The stock options granted to Ray Kurzweil expire on July 22, 2033. After that expiration date, any unexercised options become worthless, so they are exercisable only between vesting and this stated expiration date, subject to applicable plan and agreement terms.

How many United Therapeutics (UTHR) shares does Ray Kurzweil hold after these awards?

Following the reported awards, Ray Kurzweil directly holds 13,320 shares of United Therapeutics common stock. This figure reflects his direct ownership position after the grant of the restricted stock units and stock options reported in this insider transaction.

Do the United Therapeutics (UTHR) restricted stock units granted to Ray Kurzweil have an expiration date?

The restricted stock units reported do not have an expiration date. A footnote clarifies that restricted stock units do not carry an expiration, and each unit instead represents a right to receive one share of common stock after the applicable vesting conditions are satisfied.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KURZWEIL RAY

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock13,320D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0.00(1)07/22/2026A380(2)06/25/2027(3) (4)Common Stock380$0.00380D
Stock Option$527.0707/22/2026A1,190(2)06/25/2027(3)07/22/2033Common Stock1,190$0.001,190D
Explanation of Responses:
1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. Annual non-employee director award.
3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
4. Not applicable as restricted stock units do not have an expiration date.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney07/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)